Avid Bioservices

Avid Bioservices, Inc. engages in the commercial manufacturing. The firm focuses on the biopharmaceutical products derived from mammalian cell culture for culture for biotechnology and pharmaceutical companies. It specializes in clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory submissions and support. The company was founded on June 3, 1981 and is headquartered in Tustin, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Avid Bioservices Achieves Record Revenues, Faces Margin Challenges

Avid Bioservices achieved record revenues and strong bookings, but faced challenges with decreased gross margins and increased expenses. Moving into the viral vector space and with a strong late-phase project pipeline, the company sees opportunities for growth in the next 12 to 15 months.

Avid Bioservices reports Q2 earnings, focuses on expansion and innovation

Avid Bioservices showcased positive operational performance with increased utilization of the new mammalian line fleet and a record backlog. While facing challenges related to net loss and revenue recognition delays, the company remains focused on expansion and innovation, presenting opportunities for growth in the cell and gene therapy space and later-stage products.

Avid Bioservices reports robust Q3 earnings and targets pharma growth

Avid Bioservices delivered strong financial results in Q3 2023, showcasing revenue growth and operational efficiency.
While facing challenges in margins and expenses, the company's strategic focus on quality and growth presents opportunities for expansion.
With a solid cash position, record backlog, and targeted business development, Avid is poised for continued success in the market.

Avid Bioservices reports record revenues and backlog, eyes strategic growth

Avid Bioservices delivered a strong performance in Q4 2023, marked by record revenues and backlog, showcasing operational efficiency and market demand.
While facing challenges such as margin impact and resource allocation shifts, the company remains optimistic about its growth prospects and revenue stability.
Strategic opportunities lie in leveraging the strong backlog, cash flow, and planned CapEx to drive future growth and operational excellence.

Avid Bioservices reports revenue growth and expansion plans for 2024

Avid Bioservices' Q1 2024 performance reflects revenue growth and strategic investments in expanding capacity and capabilities.
While facing challenges in gross margins and profitability, the company's progress on the new facility signals future growth potential.
Opportunities lie in leveraging the completed facility to drive revenue, enhance market competitiveness, and address analyst concerns for improved performance.

Avid Bioservices reports record backlog and growth opportunities for 2024

Avid Bioservices showcased financial resilience with an improved cash position and strong backlog, despite facing revenue challenges. The company's focus on new services, customer diversity, and operational efficiency bodes well for future growth.

Avid Bioservices reports revenue growth and strategic expansions in Q3

Avid Bioservices reported strong revenue growth and backlog performance in Q3, while facing revenue decline and cost challenges compared to the previous year. Strategic expansions and operational refinements position the company for future opportunities in a competitive market landscape.

Avid Bioservices reports revenue growth and new projects, faces cost challenges

Avid Bioservices reported positive revenue growth and secured new project agreements, positioning the company for future expansion.
Despite challenges such as increased SG&A expenses and a net loss, Avid's focus on capacity utilization and new programs offers growth potential.
Addressing operational challenges and uncertainties while capitalizing on opportunities can drive Avid Bioservices towards improved financial performance.
The company's financial stability, strong backlog, and focus on profitability highlight a resilient business strategy amidst industry dynamics.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avid Bioservices, Inc. engages in clinical and commercial manufacturing of biologics. It focuses on the biopharmaceutical products derived from mammalian cell culture for culture for biotechnology and pharmaceutical companies. It specializes in clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory submissions and support. The company was founded on June 3, 1981 and is headquartered in Tustin, CA.

Accomplished Operations Professional Promoted from Role as Director of Project Engineering; Credited with Leading All of the Company's Ongoing Facility Expansion Projects Accomplished Operations Professional Promoted from Role as Director of Project Engineering; Credited with Leading All of the Company's Ongoing Facility Expansion Projects

Avid Bioservices Appoints Michael Alston, Jr. as Vice President, Operations

TUSTIN, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the Morgan Stanley 20th Annual Global Healthcare Conference. Nick Green, president and chief executive officer of Avid Bioservices, will be the featured speaker in a fireside chat at the conference, which will take place September 12-14, 2022, in New York City.

Avid Bioservices to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

Avid Bioservices, Inc. (NASDAQ:CDMO ) Q1 2023 Earnings Conference Call September 6, 2022 4:30 PM ET Company Participants Tim Brons - Investor Relations Nick Green - President and Chief Executive Officer Dan Hart - Chief Financial Officer Matt Kwietniak - Chief Commercial Officer Conference Call Participants Thomas Kelliher - RBC Capital Markets Jacob Johnson - Stephens Matt Hewitt - Craig-Hallum Paul Knight - KeyBanc Operator Good day, ladies and gentlemen. Welcome to the Avid Bioservices First Quarter Fiscal 2023 Financial Results Conference Call.

Avid Bioservices, Inc. (CDMO) Q1 2023 Earnings Call Transcript

Avid Bioservices (CDMO) delivered earnings and revenue surprises of 33.33% and 7.92%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?

Avid Bioservices (CDMO) Beats Q1 Earnings and Revenue Estimates

-- Recorded First Quarter Revenue of $36.7 Million -- -- Signed $41 Million in Net New Business Orders and Ended the Quarter with a Record High  Backlog of $157 Million --

Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2022 and Recent Developments

Biopharmaceutical Executive with More than 30 Years of Experience With Top Global Big Pharma Companies GSK and Bristol Myers Squibb Biopharmaceutical Executive with More than 30 Years of Experience With Top Global Big Pharma Companies GSK and Bristol Myers Squibb

Avid Bioservices Appoints Pramthesh (Prem) Patel, Ph.D., as Vice President, Process Development for Mammalian Cell Business

TUSTIN, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2023 on September 6, 2022 after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the first quarter and review recent corporate developments.

Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2023 After Market Close on September 6, 2022

Avid Bioservices, Inc. (NASDAQ:CDMO ) Q4 2022 Earnings Conference Call June 29, 2022 4:30 PM ET Company Participants Tim Brons - Investor Relations Nick Green - President and Chief Executive Officer Dan Hart - Chief Financial Officer Matt Kwietniak - Chief Commercial Officer Conference Call Participants Sean Dodge - RBC Capital Markets Jacob Johnson - Stephens Matt Hewitt - Craig-Hallum Capital Operator Good day ladies and gentlemen and welcome to the Avid Bioservices Fourth Quarter and Fiscal Year End 2022 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call maybe recorded.

Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q4 2022 Results - Earnings Call Transcript

-- Recorded Fourth Quarter and Full Fiscal Year Revenue of $31 Million and $120 Million, Respectively -- -- Signed $44 Million in Net New Business Orders and Ended the Quarter with a Record High Backlog of $153 Million --

Avid Bioservices Reports Financial Results for Fourth Quarter and Full Fiscal Year Ended April 30, 2022 and Recent Developments

TUSTIN, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the quarter and fiscal year ended April 30, 2022 on June 29, 2022 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the quarter and FY ended April 30, 2022 and review recent corporate developments.

Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2022 After Market Close on June 29, 2022

53,000-square-foot facility addresses unique demands of commercial-scale viral vector production COSTA MESA, Calif. , June 16, 2022 /PRNewswire/ -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing services for biotechnology and pharmaceutical companies, today highlighted the companies' collaborative efforts that enabled the phase-one opening of its new purpose-built, 53,000-square-foot viral vector and CGMP facility in Costa Mesa, California, in only eight months.

Avid Bioservices, Inc. and CRB highlight efforts that enabled opening of first phase of new viral vector facility in California in only eight months

AD/PD Laboratories Open Exactly Eight Months After Announced Plans to Build Viral Vector Facility

Avid Bioservices Announces Launch of Analytical and Process Development Suites Within New, World-Class Viral Vector Development and Manufacturing Facility

New Laboratories Have Potential to Support an Additional $20 Million in Annual Process Development Revenue, Doubling Current Mammalian Cell Process Development Capacity

Avid Bioservices Announces Further Expansion of Process Development Capacity for Mammalian Cell Business

TUSTIN, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that the company will participate in the KeyBanc Capital Markets Life Sciences & MedTech Forum. Nick Green, president and chief executive officer of Avid Bioservices, will be the featured speaker in a fireside chat at the conference, which will take place March 22-23, 2022 in a virtual format.

Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Forum

Avid Bioservices' (CDMO) CEO Nick Green on Q3 2022 Results - Earnings Call Transcript

TUSTIN, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the third quarter of fiscal year 2022 on March 8, 2022 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the third quarter and review recent corporate developments.

Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2022 after Market Close on March 8, 2022

Avid Bioservices (CDMO) closed the most recent trading day at $21.25, moving -1.16% from the previous trading session.

Avid Bioservices (CDMO) Stock Sinks As Market Gains: What You Should Know

Avid Bioservices (CDMO) closed at $18.97 in the latest trading session, marking a +0.53% move from the prior day.

Avid Bioservices (CDMO) Gains But Lags Market: What You Should Know

One unduly sold-off company of late is Avid Bioservices, with only positive news of late guiding to performance beyond expectations.

Avid Bioservices Expands Production Capacity To Continue Growth Trajectory

Milestone Marks Completion of First Phase of Two-Part Myford Facility Expansion; First Customer Project to Begin in New Downstream Processing Suite in Coming Month Milestone Marks Completion of First Phase of Two-Part Myford Facility Expansion; First Customer Project to Begin in New Downstream Processing Suite in Coming Month

Avid Bioservices Announces Official Opening of Second Downstream Processing Suite Within Myford North Facility

Gilead Sciences

Regeneron Pharmaceuticals

3 Biopharma Stocks Displaying Relative Strength Heading Into 2022

Follow The Leader: 3 Biopharma Stocks Displaying Relative Strength

Avid Bioservices (CDMO) has been struggling lately, but the selling pressure may be coming to an end soon.

Avid Bioservices (CDMO) Sees Hammer Chart Pattern: Time to Buy?

The heavy selling pressure might have exhausted for Avid Bioservices (CDMO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Avid Bioservices (CDMO) Loses 24.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Avid Bioservices (CDMO) delivered earnings and revenue surprises of 400% and 4.44%, respectively, for the quarter ended October 2021. Do the numbers hold clues to what lies ahead for the stock?

Avid Bioservices (CDMO) Tops Q2 Earnings and Revenue Estimates

Avid Bioservices, Inc.'s (CDMO) CEO Nick Green on Q2 2022 Results - Earnings Call Transcript

News for Avid Bioservices Stock (CDMO)